Emerging Company Profile

Vigil: restoring the vigilance of microglia

Emerging Company Profile: After debuting with $50M, Atlas’ Vigil plans to pursue rare microgliopathies with assets from Amgen

The Atlas incubated biotech will use its $50 million series A to advance in-licensed assets from Amgen in rare genetic disorders that affect the brain’s white matter.

Incubated by Atlas Venture